View Clinical Trial (Medical Research Study)
Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors - NCT00415571-89144(Clinical Trial 159457)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Las Vegas |
|
State:
|
|
NV |
| Zip Code: |
|
89144 |
| Conditions: |
|
Hypogonadism - Erectile Dysfunction |
| Purpose: |
|
The objective of the study is to assess and compare the preliminary efficacy, safety and
tolerability of fispemifene 300 mg and placebo given once daily for 8 weeks in the treatment
of hypogonadal men with erectile dysfunction (ED) unresponsive to PDE5 inhibitors.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Hypogonadal (morning total testosterone levels ≤400 ng/dl) men age ≥20 with ED who
are unresponsive to PDE5 inhibitors, as demonstrated by International Index of
Erectile Function (IIEF) results for 28-day lead in period. |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 1, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|